Depression in Sjögren’s Disease Extends Beyond Physical Symptom Burden

Depression in Sjögren’s disease (SjD) may reflect more than the strain of chronic dryness, pain, and fatigue. A narrative review in the Journal of International Medical Research examines how psychosocial stressors and possible immune and neurologic mechanisms intersect, and why depression deserves attention alongside systemic disease activity. Here’s a brief look at what it found.

Depression Risk Is Elevated, but Estimates Vary Widely

The authors synthesized 40 SjD-related sources and 9 contextual references. Reported depression prevalence ranged from 3.2% to 78.6%, largely because studies used different populations, diagnostic criteria, and assessment instruments. A meta-analysis of 12 studies involving 1,917 patients found more than fivefold higher odds of depression in SjD than in healthy controls (odds ratio [OR], 5.36; 95% CI, 4.05–7.09).

A nationwide cohort of 2,686 patients with primary SjD and 10,744 controls also identified an increased risk of developing depressive disorders (adjusted hazard ratio, 1.8; 95% CI, 1.4–2.3). These findings support mental health surveillance, particularly during the first 5 years after diagnosis.

Immune and Neurologic Pathways May Contribute

Chronic symptoms and psychosocial pressures are likely contributors, but investigators are also exploring neuroimmune links. In a 60-patient study, elevated interleukin-6 levels were associated with depression. Other proposed mechanisms include inflammatory effects on tryptophan-serotonin metabolism, autoantibodies, gut dysbiosis, and neurovascular abnormalities.

Neuroimaging studies have described white matter changes, reduced gray matter volume, and cerebral hypoperfusion in SjD. However, these associations do not establish causality, and much of the mechanistic evidence comes from small, observational studies.

Symptom Burden and Disease Activity Tell Different Stories

Psychological distress does not consistently parallel systemic disease activity. Across cohorts, fatigue, pain, dryness, and depression often correlate more closely with quality-of-life impairment than with objective inflammatory measures.

In a study involving 639 patients with primary SjD, pain and depression together accounted for 48% of the variability in health-related quality-of-life utility scores after adjustment for age and sex. This disconnect suggests that patients with substantial fatigue or functional impairment may require psychological assessment even when systemic disease activity appears controlled.

Screening Requires Attention to Symptom Overlap

The Patient Health Questionnaire-9 includes fatigue, sleep, and appetite items that overlap with SjD manifestations. The Hospital Anxiety and Depression Scale may offer an advantage because its depression subscale excludes somatic symptoms.

Neither instrument has been rigorously validated specifically for SjD, so positive screens require clinical interpretation. New cognitive decline or neurologic symptoms warrant further evaluation, while suicidal ideation requires urgent assessment.

Treatment Must Account for Sicca Symptoms

Management should integrate psychological therapies, lifestyle interventions, and individualized pharmacologic treatment. Selective serotonin reuptake inhibitors are frequently considered first-line, although agents with substantial anticholinergic activity, including paroxetine and tricyclic antidepressants, may worsen oral and ocular dryness.

Duloxetine may be considered when depression coexists with chronic pain, with monitoring for xerostomia. Optimizing systemic disease control may offer secondary psychological benefits, but immunosuppression solely for depressive symptoms is not supported.

The review was narrative, without formal risk-of-bias assessment, and SjD-specific treatment evidence remains limited. Its findings reinforce the value of integrating mental health assessment into routine SjD care, particularly for patients with persistent fatigue, pain, sleep disturbance, or functional decline. Further research should validate screening tools and clarify whether neuroimmune mechanisms can inform more targeted interventions.

Reference:
Galindo-Donaire JR, Vázquez-Hernández AE, Hernández-Molina G. Sjögren's disease and depression. J Int Med Res. 2026;54(10):3000605261494354. doi:10.1177/03000605261494354